Rafferty Asset Management’s Anika Therapeutics ANIK Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-28,114	Closed	-$730K	–	1076
2023 Q2	$730K	Sell	28,114 -878	-3%	-$23.5K	﹤0.01%	898
2023 Q1	$833K	Buy	28,992 +880	+3%	+$26.2K	0.01%	844
2022 Q4	$832K	Sell	28,112 -240	-0.8%	-$6.83K	0.01%	799
2022 Q3	$675K	Buy	28,352 +14,210	+100%	+$327K	0.01%	788
2022 Q2	$316K	Sell	14,142 -15,499	-52%	-$346K	﹤0.01%	906
2022 Q1	$744K	Buy	29,641 +6,363	+27%	+$194K	﹤0.01%	842
2021 Q4	$834K	Buy	23,278 +8,586	+58%	+$344K	﹤0.01%	951
2021 Q3	$625K	Sell	14,692 -6,025	-29%	-$248K	﹤0.01%	994
2021 Q2	$897K	Sell	20,717 -7,774	-27%	-$331K	0.01%	952
2021 Q1	$1.16M	Buy	28,491 +23,112	+430%	+$877K	0.01%	740
2020 Q4	$243K	Sell	5,379 -6,512	-55%	-$247K	﹤0.01%	922
2020 Q3	$421K	Buy	11,891 +4,549	+62%	+$164K	0.01%	736
2020 Q2	$277K	Buy	+7,342	New	+$242K	﹤0.01%	850
2020 Q1	–	Sell	-18,719	Closed	-$971K	–	609
2019 Q4	$971K	Sell	18,719 -5,192	-22%	-$302K	0.01%	560
2019 Q3	$1.31M	Buy	23,911 +1,145	+5%	+$58.8K	0.02%	482
2019 Q2	$925K	Buy	22,766 +2,108	+10%	+$76.9K	0.02%	571
2019 Q1	$625K	Buy	+20,658	New	+$708K	0.01%	626